Abstract
Also clinical cardiologists and internists not working in specialized oncology centers facing with cancer patients must know (1) possible toxicity of a chemotherapy agent or of radiotherapy; (2) possible factors, either risk factors or a preexisting cardiovascular disease, predisposing to the development of cardiotoxicity; and (3) the use of preventive and curative measures during possible cardiotoxic therapy.
Coordination between specialists reduces avoidable delay in undertaking therapy or risk of cardiac damage.
The chemotherapy era begins after World War II with the casual observation of bone marrow suppression by nitrogen mustards. In the years from 1950 to 1960 began trials and therapeutic use of the common chemotherapy agents.
The use of the association of different drugs began after the use of single agents and after the impressive progression of the knowledge of cell biology and of target therapy with tyrosine kinase inhibitors and with monoclonal antibodies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Jemal A. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277.
American Cancer Society. Cancer facts & figures 2010 (online). 2010.
National Cancer Institute. SEER cancer statistic review 1975–2006. Table 1.21 (online). 2009.
Ferlay J. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765.
Ever MS. A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin. 2011;7:363.
Albini A. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol. 2011;7:693.
Weisse AB. Medical odysseys: the different and sometimes unexpected pathways to twentieth-century medical discoveries. New Brunswick: Rutgers University Press; 1991. p. 127.
Tan C. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20(3):333.
Druker BJ. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408.
GLOBOCAN 2012. Cancer incidence and mortality worldwide – IARC, 2010. http://globocan.iarc.fr.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mather C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 (Internet). Lyon: International Agency for research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed 1 Aug 2014.
Howlader N, Noone AM, Krapcho M, editors. SEER cancer statistics review, 1975–2010. Bethesda: National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
Cancer Research UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Asteggiano, R., Esquivias, G.B. (2015). Introduction. In: Baron Esquivias, G., Asteggiano, R. (eds) Cardiac Management of Oncology Patients. Springer, Cham. https://doi.org/10.1007/978-3-319-15808-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-15808-2_1
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-15807-5
Online ISBN: 978-3-319-15808-2
eBook Packages: MedicineMedicine (R0)